Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo ...

The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...

CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for ...

Solengepras shows strong potential as an adjunctive therapy for Parkinson’s, offering a novel, well-tolerated option with ...

Solengepras, the most advanced investigational treatment in Cerevance’s pipeline, is an oral, non-dopaminergic therapy in Phase 3 development for Parkinson’s disease. A brain-penetrant, specific ...

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...

UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...

UK-based pharmaceutical company Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate ...

US-based biotech Cerevance is continuing an ongoing pivotal study of its Parkinson’s disease candidate despite it showing no benefit compared to placebo in a Phase II study. The biotech ...

Additional Cerevance Presentations at AAN 2025 The company presented a poster demonstrating the potential of its proprietary NETSseq platform to identify and/or validate cell-specific gene targets ...